
    <html>
    <head><title>WEED.TO</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2><span style='color:#1e66f5; font-weight:900; margin-right:10px;'>quarterly results d</span> WEED.TO  
        <span style='font-weight:normal; font-size: 18px;'>(41d - Debt restructuring)</span>
        <span style='color:black; font-weight:bold; font-size: 20px;'> </span>
        <a href='https://finance.yahoo.com/chart/WEED.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  â€” </span>
    </h2>

    <div class="container">
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='neg-light'><td>2025-11-18</td><td>-0.30</td><td></td><td>product launches</td><td>-0.3 local feel              __   WEED.TO __    -> i:0.3<-                      <br><br>FEELING: total score -0.3 Reasoning: Here's a breakdown of the score based on the provided news and the defined events: Product Launches (+0.2): The expansion of Spectrum Therapeutics in Australia with new softgel capsules is a product launch. While positive, the overall negative sentiment surrounding the company limits the positive impact. Analyst Meetings (-0.1): The "Buy" rating with a C$8.00 target is a minor positive, but the TipRanks AI Analyst rating it as "Underperform" significantly diminishes this. Financial Performance (-0.3): The news explicitly mentions "poor financials," "significant losses," and "negative cash flows." This is a major negative and carries significant weight. Technical Sentiment (-0.1): "Bearish momentum" and a "Strong Sell" technical sentiment signal contribute to the negative outlook. Valuation (-0.1): The mention of a "negative P/E ratio" and "no dividend yield" indicates an unattractive valuation, adding to the negative sentiment. The negative financial performance and bearish technicals outweigh the minor positive aspects of the product expansion and analyst rating. --- <br> - Canopy Growth is expanding its Australian medical cannabis offerings, but faces significant financial headwinds. While analysts maintain a Buy rating with a C$8.00 target, the stock is flagged as Underperform due to poor financials and bearish technicals. Investors should proceed with caution. <br><br>*** REZUMAT *** - Canopy Growth expands Spectrum Therapeutics in Australia with new softgel capsules. - Analyst rating: Buy with C$8.00 price target. - TipRanks AI Analyst rates TSE:WEED as Underperform. - Financial performance is poor: significant losses and negative cash flows. - Technical analysis indicates bearish momentum. - Valuation unattractive: negative P/E ratio, no dividend yield. - Market cap: C$556.4M. - Average trading volume: 4,410,525. - Technical sentiment signal: Strong Sell.   (gemma3:12b-it-q4_K_M on 2025-11-19 00:39:31)</td><td><a href='https://www.tipranks.com/news/company-announcements/canopy-growth-expands-medical-cannabis-offerings-in-australia' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-11-15</td><td>-0.30</td><td></td><td>Guidance updates</td><td>-0.3 local feel              __   WEED.TO __    -> i:0.3<-                      <br><br>FEELING: total score -0.3 Reasoning: Stock Price Drop: A significant stock price drop (-26%) indicates negative sentiment, contributing -0.1. Declining Revenue: The news highlights declining revenue, contrasting with industry trends. This is a negative signal, contributing -0.2. High P/S Ratio: While the high P/S ratio suggests optimism, the text explicitly states it's "not sustainable" if revenue growth doesn't meet projections. This introduces risk and uncertainty, slightly offsetting the potential positive aspect. Analyst Expectations: The fact that analyst predictions (5.4%) are slightly below industry forecasts (5.7%) introduces a minor negative element, suggesting potential for disappointment. Backward-Looking Data: The mention of a 71% drop in the last 12 months is backward-looking and receives a very low score. --- <br> - Canopy Growth's stock has plummeted, and despite the drop, its P/S ratio remains high relative to industry peers and analyst expectations. Investors should be cautious, as the current price may not be sustainable if revenue growth doesn't meet optimistic projections. <br><br>*** REZUMAT *** - WEED stock dropped 26% recently, down 71% in the last 12 months. - P/S ratio is 1.9x, higher than most Canadian pharmaceutical companies (below 1x). - Revenue is declining, unlike industry trends. - Analysts predict 5.4% annual revenue growth over three years. - Industry forecasts 5.7% annual revenue growth. - High P/S suggests investor optimism exceeding analyst forecasts. - Potential risk of disappointment if revenue growth lags.   (gemma3:12b-it-q4_K_M on 2025-11-15 23:01:22)</td><td><a href='https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsx-weed/canopy-growth-shares/news/canopy-growth-corporations-tseweed-26-dip-still-leaving-some-1' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-07</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   WEED.TO __    -> i:0.3<-                      <br><br>FEELING: total score: 0.3 --- <br> - Canopy Growth shows strong revenue growth and reduced losses, indicating improved profitability; still operating at loss but narrowing, making it a potential upside play if market conditions remain favorable. <br><br>*** REZUMAT *** - Revenue Q3 2025: $82.998B, up from $73.958B YoY. - Gross margin: $21.905B, slightly higher than $21.838B. - Operating loss: $(16.894)B, improved from $(45.943)B. - Net loss: $(1.639)B, vs $(131.55)B previous year. - Loss per share: $(0.01), vs $(1.48) in 2024. - Canada revenue: $45.760B, growth YoY. - Germany revenue: $12.725B; US revenue: $6.371B. - Focus on operational optimization and market expansion.   (gpt-oss:20b on 2025-11-09 10:56:13)</td><td><a href='https://www.tradingview.com/news/tradingview:ab521b48e65f6:0-canopy-growth-corp-sec-10-q-report/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-10-29</td><td>0.20</td><td></td><td>Lawsuit settlement</td><td>0.2 local feel              __   WEED.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news primarily revolves around the resolution of litigation with Verano Holdings. This falls under the category of "lawsuits" and specifically, a "favorable resolution." The settlement of $10 million, including assets and cash, removes a legal overhang, which is generally viewed positively. The phrase "potentially positive for investor confidence" further reinforces this. While the settlement amount is significant, it's not explicitly stated to be accretive to DCF or EPS, so the positive impact is moderate. The future impact is the removal of uncertainty and the ability to focus on strategic priorities. The settlement date in 2025 is far in the future, which reduces the immediate impact. Therefore, a score of 0.2 reflects a modest positive impact. --- <br> - Vireo Growth resolves litigation with Verano Holdings, receiving $10 million (assets & cash). This removes a legal overhang and allows both companies to focus on strategic priorities, potentially positive for investor confidence. <br><br>*** REZUMAT *** - Vireo Growth and Verano Holdings settled all pending litigation. - Settlement approved by both companies' boards of directors. - Vireo receives approximately US$10 million from the settlement. - Includes acquisition of real estate assets and $1 million cash. - Settlement finalized on October 29, 2025.   (gemma3:12b-it-q4_K_M on 2025-10-30 04:05:38)</td><td><a href='https://www.cannabisbusinesstimes.com/business-issues-benchmarks/canadian-cannabis-market/news/15770489/vireo-growth-verano-holdings-reach-settlement-on-litigation' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-10-23</td><td>-0.30</td><td></td><td>quarterly results</td><td>-0.3 local feel              __   WEED.TO __    -> i:0.3<-                      <br><br>FEELING: total score -0.3 Assessment: Market Sentiment/Index Performance: The news highlights a significant downturn in the Global Cannabis Stock Index (-8.5% in October), indicating negative market sentiment. This contributes to a score of -0.1. The YTD gain of 2.2% is a minor positive, but overshadowed by the recent decline. Potential Rescheduling & 280E Taxation: The mention of potential rescheduling and its potential impact on 280E taxation is a significant negative. Eliminating 280E would be a substantial financial hit, contributing a score of -0.2. Lack of Institutional Buying: The news explicitly mentions a lack of institutional buying and trader-driven activity, which poses risks. This contributes a score of -0.1. Performance of Specific Stocks: While some stocks (Verano Holdings, Tilray Brands) show positive performance, the overall tone is negative due to the broader market decline and concerns. Backward-Looking Data: The YTD gains/losses and comparisons to the S&P 500 are largely backward-looking and receive a low score. Note: The overall score reflects the prevailing negative sentiment and potential financial headwinds facing WEED.TO, as indicated by the news. --- <br> - Cannabis stocks are facing significant headwinds, with the Global Cannabis Stock Index down 8.5% in October and only up 2.2% year-to-date. Concerns around financials, potential rescheduling, and a lack of institutional buying suggest further declines are possible. Investors should proceed with caution. <br><br>*** REZUMAT *** - Global Cannabis Stock Index down 8.5% in October, YTD gain of 2.2%. - MSOS down 7.3% in October, up 16.5% YTD. - Curaleaf, Trulieve, and Green Thumb Industries down: -3.9%, -8.8%, -9.9%. - Verano Holdings up 7.7% in October, a top performer. - Potential rescheduling could eliminate 280E taxation. - Ancillaries are favored, cannabis REITs are recommended. - Canopy Growth down 51.8% YTD, Tilray Brands up 9.0% YTD. - S&P 500 up 14.9% YTD, outperforming cannabis stocks. - Lack of institutional buying and trader-driven activity pose risks.   (gemma3:12b-it-q4_K_M on 2025-10-24 02:44:32)</td><td><a href='https://www.newcannabisventures.com/cannabis-stocks-could-get-crushed-further/' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    